By Kailyn Rhone
NeuroPace expects to report a rise in fourth quarter and full-year sales.
The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%.
For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million.
Cash and short-term investments as of Dec. 31 are expected to be $52.8 million.
NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
January 08, 2025 17:02 ET (22:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。